QUOTE AND NEWS
Mondo Visione  Jun 19  Comment 
On June 13, 2017, the Securities and Exchange Commission of Brazil approved the change to the corporate name of BM&FBOVESPA S.A. – Bolsa de Valores, Mercadorias e Futuros to B3 S.A. – Brasil, Bolsa, Balcão, which must be used in all formal...
Mondo Visione  May 31  Comment 
B3’s Extraordinary General Meeting of May 10, 2017 approved the corporate name of BM&FBOVESPA S.A. – Bolsa de Valores, Mercadorias e Futuros being changed to B3 S.A. – Brasil, Bolsa, Balcão. On May 15, 2017, we formally submitted a...
FierceBiotech  May 24  Comment 
​​​​​​​Cel-Sci’s pitch to get a partial clinical hold lifted by the FDA has gone awry. The drugmaker set out a plan to get clinical development of Multikine moving forward again, only for the FDA to pick apart its proposal and...
SeekingAlpha  May 10  Comment 
Mondo Visione  Apr 17  Comment 
Brazilians will soon have new opportunities for trading and portfolio diversification in securities issued by foreign companies. On April 5, the Securities and Exchange Commission of Brazil (CVM) released Instruction 585 authorizing...




 

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is an immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki